Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare and Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community

The Centers for Medicare and Medicaid Services (CMS) published initial1 and revised2 guidance describing how the agency will implement the “Drug Price Negotiation Program” (DPNP) (quotation marks around the words “negotiate” and “negotiation” specify that these are terms used by the agency in their publications. Many manufacturers believe the process described by the agency does not provide a genuine opportunity to negotiat e, and this is one factual allegation most common among lawsuits filed against the Department of Health and Human Services in response to the Inflation Reduction Act [IRA] implementation) provisions of IRA.

Source: Value in Health - October 10, 2023 Category: International Medicine & Public Health Authors: John M. O ’Brien, Jan Elias Hansen Tags: Commentary Source Type: research